Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific immune responses in patients with triple-negative breast cancer, according to a study published online Nov. 14 in Genome ...
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of scheduleSITC 2024 ...
Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...
Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc ...
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback